Context
- In May 2026, a landmark global consensus published in The Lancet and spearheaded by the Endocrine Society and Monash University officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
- This change, resulting from a 14-year international effort, aims to move beyond a “cyst-centric” definition toward a systemic understanding of the disorder. In the Indian context—where prevalence is estimated at 16–18%—this reclassification is vital for addressing the high burden of metabolic and insulin-related disorders among women.
1. The Anatomy of the New Nomenclature (PMOS)
The new name is designed to be a more accurate scientific descriptor of the condition’s multi-systemic impact:
- Polyendocrine: Reflects that the disorder is not localized to the ovaries but involves multiple hormonal systems, including the Hypothalamus-Pituitary-Ovarian (HPO) axis, adrenal glands, and pancreatic insulin regulation.
- Metabolic: Highlights the core pathophysiology—Insulin Resistance. This dimension is critical as it links the condition to long-term risks like Type 2 Diabetes, Cardiovascular Disease, and Non-Alcoholic Fatty Liver Disease (NAFLD).
- Ovarian: Retains the reproductive element, acknowledging the disruption in ovulation and androgen (male hormone) production.
- Syndrome: Confirms it is a collection of symptoms rather than a single disease with a singular cause.
2. Why was the Renaming Necessary?
The shift from PCOS to PMOS addresses several critical medical and social gaps:
- Correcting a Misnomer: The term “Polycystic” was misleading. The “cysts” are actually arrested follicles (eggs that failed to mature) rather than true clinical cysts.
- Reducing Diagnostic Delay: Previously, many women were denied a diagnosis if their ultrasound did not show “cysts,” despite having metabolic or hormonal symptoms. PMOS allows for diagnosis based on broader endocrine markers.
- Destigmatization: By removing the “Ovary-first” focus, the name reduces the heavy stigma associated with fertility and reproductive “failure,” framing it instead as a manageable metabolic health journey.
- Inclusion of Adolescents: Since ultrasounds are less reliable in teenagers, the “PMOS” framework allows doctors to focus on early metabolic and hormonal signals (like severe acne or insulin spikes) in younger patients.
3. Comparative Dimensions: PCOS vs. PMOS
| Feature | Polycystic Ovary Syndrome (PCOS) | Polyendocrine Metabolic Ovarian Syndrome (PMOS) |
| Primary Focus | Gynecological / Ovarian morphology | Systemic / Endocrine & Metabolic health |
| Key Symptom | Ovarian “cysts” (visualized on USG) | Hormonal imbalance & Insulin Resistance |
| Clinical Goal | Often limited to achieving pregnancy | Long-term prevention of chronic diseases |
| Associated Risks | Infertility, Irregular periods | Diabetes, Heart Disease, Anxiety, Obesity |
Consider the following statements regarding Polycystic Ovary Syndrome / PMOS:
1. The term PMOS highlights the role of endocrine and metabolic dysfunctions such as insulin resistance.
2. Under the PMOS framework, diagnosis depends only on the presence of ovarian cysts in ultrasound imaging.
3. The renaming from PCOS to PMOS aims to reduce stigma and broaden diagnosis beyond reproductive symptoms alone.
Which of the statements given above are correct?
(a) 1 and 2 only
(b) 1 and 3 only
(c) 2 and 3 only
(d) 1, 2 and 3
Answer:
(b) 1 and 3 only
Explanation:
• Statement 1 is correct: PMOS emphasizes endocrine and metabolic dimensions, especially insulin resistance.
• Statement 2 is incorrect: PMOS moves beyond a cyst-centric diagnosis and includes broader hormonal and metabolic indicators.
• Statement 3 is correct: The renaming seeks to reduce stigma and promote a systemic understanding of the disorder.
